The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches?

被引:262
作者
Roth, BL
Lopez, E
Patel, S
Kroeze, WK
机构
[1] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA
关键词
serotonin receptors; antidepressant; antipsychotic; clozapine; fluoxetine;
D O I
10.1177/107385840000600408
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A large number of 5-HT receptors (>15) have been identified by molecular cloning technology over the past 10 years. This review briefly summarizes available information regarding the functional and therapeutic implications of serotonin receptor diversity for neurology and psychiatry. 5-HT receptors are divided into seven main families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Several families (e.g., 5-HT1 family) have many members (e.g., 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), each of which is encoded by a distinct gene product. In addition to the genomic diversity of 5-HT receptors, splice variants and editing isoforms exist for many of the 5-HT receptors, making the family even more diverse. Evidence that is summarized in this review suggests that 5-HT receptors represent novel therapeutic targets for a number of neurologic and psychiatric diseases including migraine headaches, chronic pain conditions, schizophrenia, anxiety, depression, eating disorders, obsessive compulsive disorder, pervasive developmental disorders. and obesity-related conditions (Type II diabetes, hypertension, obesity syndromes). It is possible that subtype-selective serotonergic agents may revolutionize the treatment for a number of medical, psychiatric, and neurological disorders.
引用
收藏
页码:252 / 262
页数:11
相关论文
共 104 条
[1]   DIFFERENTIAL EFFECT OF SUBCHRONIC TREATMENT WITH VARIOUS NEUROLEPTIC AGENTS ON SEROTONIN2 RECEPTORS IN RAT CEREBRAL-CORTEX [J].
ANDREE, TH ;
MIKUNI, M ;
TONG, CY ;
KOENIG, JI ;
MELTZER, HY .
JOURNAL OF NEUROCHEMISTRY, 1986, 46 (01) :191-197
[2]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[3]   The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial [J].
Berman, RM ;
Anand, A ;
Cappiello, A ;
Miller, HL ;
Hu, XS ;
Oren, DA ;
Charney, DS .
BIOLOGICAL PSYCHIATRY, 1999, 45 (09) :1170-1177
[4]   Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings [J].
Blier, P ;
Bergeron, R .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 (01) :37-44
[5]   The central 5-HT3 receptor in CNS disorders [J].
Bloom, FE ;
Morales, M .
NEUROCHEMICAL RESEARCH, 1998, 23 (05) :653-659
[6]   5-HT4 receptors:: Gene, transduction and effects on olfactory memory [J].
Bockaert, J ;
Claeysen, S ;
Sebben, M ;
Dumuis, A .
ADVANCES IN SEROTONIN RECEPTOR RESEARCH: MOLECULAR BIOLOGY, SIGNAL TRANSDUCTION, AND THERAPEUTICS, 1998, 861 :1-15
[7]   The 5-hydroxytryptamine, receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum [J].
Boess, FG ;
Riemer, C ;
Bös, M ;
Bentley, J ;
Bourson, A ;
Sleight, AJ .
MOLECULAR PHARMACOLOGY, 1998, 54 (03) :577-583
[8]   RS-102221: A novel high affinity and selective, 5-HT2C receptor antagonist [J].
Bonhaus, DW ;
Weinhardt, KK ;
Taylor, M ;
Desouza, A ;
Mcneeley, PM ;
Szczepanski, K ;
Fontana, DJ ;
Trinh, J ;
Rocha, CL ;
Dawson, MW ;
Flippin, LA ;
Eglen, RM .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :621-629
[9]  
Bouchelet I, 1996, MOL PHARMACOL, V50, P219
[10]   Involvement of 5-HT6 receptors in nigro-striatal function in rodents [J].
Bourson, A ;
Boess, FG ;
Bös, M ;
Sleight, AJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (07) :1562-1566